All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Wang Expands on the Continued Investigation of Targeted Therapies in Relapsed/Refractory AML

June 6th 2024

Eunice S. Wang, MD, discusses current unmet needs and efforts to move menin inhibitors into earlier lines of therapy in relapsed/refractory AML.

Unveiling the Future of Oncology: Specialized Teams at Florida Cancer Specialists & Research Institute Target Advanced Cancer Treatments

June 6th 2024

Florida Cancer Specialists & Research Institute, LLC announces the introduction of designated Disease SiteTeams for late-phase research & the subsequent formation of the FCS Disease Site Committee.

New Data With RP1 Plus Nivolumab in PD-1–Refractory Melanoma Build on Positive Findings

June 6th 2024

The combination of RP1 and nivolumab was safe and effective in patients with anti–PD-1-failed advanced melanoma.

Nivolumab/Cabozantinib Combination Prolongs Treatment-Free Survival in Advanced RCC

June 6th 2024

Partition overall survival data indicated that nivolumab plus cabozantinib extended treatment-free survival vs sunitinib in advanced renal cell carcinoma.

High CR Rate in NMIBC Is Maintained by Cretostimogene Grenadenorepvec Plus Pembrolizumab

June 6th 2024

Cretostimogene grenadenorepvec plus pembrolizumab sustains high CR rate in NMIBC according to the phase 2 CORE-001 trial.

Intensification With Apalutamide/ADT Improves PSA PFS in Biochemically Recurrent Prostate Cancer

June 6th 2024

Apalutamide/ADT maintains quality of life, demonstrates improved PSA progression-free survival in recurrent prostate cancer according to PRESTO trial.

Advancements With Combination Therapies in RCC Usher in New Questions

June 6th 2024

Benjamin L. Maughan, MD, PharmD, discusses the implications of immuno-oncology and TKI agent combinations in clear cell and non–clear cell RCC.

Higher T-Cell Inflamed GEP Values Are Positively Associated with Outcomes For Pembrolizumab/Axitinib in ccRCC

June 5th 2024

Higher T-cell inflamed GEP values were positively associated with clinical outcomes for pembrolizumab plus axitinib in advanced clear cell RCC.

Second-Line T-DXd Data Remain Strong in HER2+ Metastatic Breast Cancer

June 5th 2024

Trastuzumab deruxtecan improved responses and survival vs T-DM1 in HER2+ metastatic breast cancer after prior exposure to trastuzumab and a taxane.

Daratumumab Retreatment Leads to Responses in Relapsed/Refractory Myeloma

June 5th 2024

Retreatment with daratumumab-based regimens led to a similar ORR vs initial daratumumab treatment in relapsed/refractory myeloma.

Enzalutamide Treatment Suspension Has No Significant Impact on QOL in nmHSPC

June 5th 2024

Treatment cessation of enzalutamide-containing regimens in responding patients had no impact on QOL in biochemically recurrent nmHSPC.

Lenvatinib Plus Pembrolizumab Delays Tumor Progression in All Organs vs Sunitinib in Advanced RCC

June 5th 2024

Lenvatinib/pembrolizumab offered a significant benefit in terms of time to disease progression in all organs vs sunitinib in advanced RCC.

UCART22 Earns Orphan Drug Designation for Acute Lymphoblastic Leukemia in Europe

June 5th 2024

The European Commission granted orphan drug designation to UCART22 for acute lymphoblastic leukemia.

Lunresertib/Camonsertib Gets Fast Tracked by FDA for CCNE1+ or FBXW7/PPP2R1A+ Ovarian Cancer

June 5th 2024

Lunresertib plus camonsertib received FDA fast track designation for select patients with platinum-resistant ovarian cancer.

Updated Analysis From MajesTEC-1 Confirms CRS Reduction With Prophylactic Tocilizumab in Relapsed/Refractory Myeloma

June 5th 2024

Updated Analysis from Phase 1/2 MajesTEC-1 trial support the use of prophylactic tocilizumab to reduce the risk of cytokine release syndrome associated with outpatient administration of teclistamab.

Exploring the Nuances of Postoperative Considerations in Pancreatic Cancer

June 5th 2024

Zyed Nabeel Zafar, MD, MPH, explores the nuances of postoperative considerations in pancreatic cancer treatment.

A Geneticist and PCP Detail Considerations With New Screening Recommendations for Breast Cancer

June 5th 2024

Brittany L. Bychkovsky, MD, MSc, and Lydia Pace, MD, MPH, explain approaches to breast cancer screening and considerations with the final USPSTF screening recommendations.

Olverembatinib Demonstrates Early Activity, Tolerability in SDH-deficient GIST

June 4th 2024

Olverembatinib showed antitumor activity in patients with TKI-resistant, SDH-deficient GISTs and paraganglioma.

TTFields Plus BSC Prolongs Time to Intracranial Progression in NSCLC Brain Metastases

June 4th 2024

TTFields therapy plus best supportive care increased time to first intracranial progression by 10.6 months in patients with NSCLC brain metastases.

Frontline Petosemtamab Doublet Elicits Responses in Recurrent/Metastatic HNSCC

June 4th 2024

Petosemtamab paired with pembrolizumab had early clinical efficacy when used as first-line treatment in select head and neck squamous cell carcinoma